Continuous Versus Intermittent cARdiac Electrical moNitorinG (CARING)
Torsades de Pointe Caused by Drug, Long QT Syndrome
About this trial
This is an interventional screening trial for Torsades de Pointe Caused by Drug
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine
- At least 18 years of age.
- No allergy to adhesive patches.
- Able to understand and willing to sign an IRB-approved written informed consent document.
Exclusion Criteria:
- Younger than 18 years of age
- Allergy to adhesive patches
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Experimental
Continuous patch monitoring system
Participants will receive standard of care treatment with either arsenic trioxide or capecitabine. They will have continuous patch monitor system (BodyGuardian Mini Plus) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment. Twelve-lead ECGs are routinely performed in patients receiving arsenic trioxide at baseline and twice weekly during the first 4 weeks of therapy. These ECGs (total of up to 9) will be accessed for the purposes of this study. Patients who receive capecitabine do not routinely have ECGs performed after baseline, but for the purposes of this study, two serial ECGs will be conducted on Day 14 and Day 28 of Cycle 1 of treatment (total of 5 including baseline).